Pharmaceutics (Oct 2022)

Novel <i>Stenotrophomonas maltophilia</i> Bacteriophage as Potential Therapeutic Agent

  • Rima Fanaei Pirlar,
  • Jeroen Wagemans,
  • Fabian Kunisch,
  • Rob Lavigne,
  • Andrej Trampuz,
  • Mercedes Gonzalez Moreno

DOI
https://doi.org/10.3390/pharmaceutics14102216
Journal volume & issue
Vol. 14, no. 10
p. 2216

Abstract

Read online

A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections.

Keywords